Children’s Hospital Association’s Post

Great news in the world of medicine - the FDA has approved selpercatinib for use in pediatric patients battling thyroid cancer. As of June 12, selpercatinib extends a lifeline to adults and children older than 2 years with certain advanced thyroid cancers. This milestone represents more than just another treatment option; clinical evidence is compelling, with a significant portion of patients showing favorable responses. While we should be mindful of the side effects, the potential benefits for individuals with RET fusion-positive thyroid cancer are too substantial to overlook. #HealthcareAdvancement #FDAApproval #MedicalInnovation

𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐋𝐮𝐭𝐚𝐭𝐡𝐞𝐫𝐚® 𝐟𝐨𝐫 𝐏𝐞𝐝𝐢𝐚𝐭𝐫𝐢𝐜 𝐆𝐄𝐏-𝐍𝐄𝐓 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 Novartis Novartis announced FDA approval of Lutathera® for pediatric patients (12 ) with somatostatin receptor-positive (SSTR ) gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lutathera is the first therapy approved for this indication in children, offering new hope for those with this rare cancer. NETs, slow-growing malignancies, often lead to delayed diagnosis. Approximately 10-20% of pediatric patients are diagnosed with metastatic disease. The approval was based on the NETTER-P trial, which showed a safety profile consistent with adult studies. Pediatric patients showed comparable radiation absorption to adults. This milestone addresses a critical need for new treatment options in young patients with GEP-NETs. #Lutathera #GEPNET #PediatricCancer #FDAApproval #NeuroendocrineTumors #CancerTreatment #RareDisease #Oncology #CancerResearch #ClinicalTrials #Novartis

According to the Journal of Clinical Oncology, a recent study found that adult childhood cancer survivors with prediabetes are at an increased risk of developing cardiovascular issues or kidney disease. (https://ow.ly/4Snk50QnQxc) The NCCS offers a free tool called the Late Effects After Treatment Tool (LEATT) – try it today to learn about potential late effects as a result of having cancer and treatments as a child. The tool also provides guidance for follow-up care and prevention tips. https://ow.ly/FZUx50QnQxi

Early Detection in Pediatric Cancers: Unique Challenges and Methods

Today on World Ovarian Cancer Day, we stand in solidarity with every person touched by this disease. Thieme supports the advancement of medical knowledge to combat ovarian cancer. Gain invaluable insights from the Indian Journal of Medical and Paediatric Oncology, which provides crucial information for healthcare professionals and patients on early detection and effective treatment. (https://lnkd.in/gdTwt7gd) Let’s spread awareness and foster hope—together we can make a difference. #WorldOvarianCancerDay #ThiemeCares #OvarianHealth #EarlyDetectionSavesLives” #WorldOvarianCancerDay #MedicalHealth #MedicalStudent #MBBSStudent #MBBSStudy #OpenAccessJournal #ThiemeCares #OvarianHealth #EarlyDetectionSavesLives #thiemeindia

Are you up to date with the latest advancements in metastatic breast cancer treatment? Join us as we explore groundbreaking evidence that challenges the traditional HER2 versus HER2- binary paradigm. Learn how specific ADCs, now beneficial for HER2-low patients, are revolutionizing treatment strategies and improving patient outcomes. This program covers the critical aspects of ADC targets and payloads, emphasizing their role in extending survival and enhancing the quality of life for patients with pretreated metastatic disease. Gain valuable insights on diagnosing, treatment, and sequencing to better address the needs of your patients. Elevate your expertise with cutting-edge insights: https://ow.ly/CyEg50Sj13x #MetastaticBreastCancer #ADCTreatment #HER2Low #ClinicalOncology #HealthcareEducation

American Society of Clinical Oncology (ASCO)24 Updates: A Multi-Ancestry Polygenic Risk Score Helps to Predict Triple-Negative Breast Cancer Holly Pederson MD, is the Director of Medical Breast Services at Cleveland Clinic and an Associate Professor at Case Western Reserve University. For more interesting content, follow and subscribe to the OncoDaily YouTube channel [https://lnkd.in/dMvn--yU] and click the bell icon to stay updated. #Cancer #OncoDaily #ClevelandClinic #BreastCancer #CancerAwareness #CancerResearch #OncoDailyASCO24Updates #ASCO24 #Oncology

Today marks another significant step forward for the #LungCancer community, with the promise of more treatment options that have the potential to transform the treatment experience for those living with this devastating disease. The U.S. FDA granted priority review of Johnson & Johnson Innovative Medicine’s application for a subcutaneous treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC). This is the first ever instance of an intravenous (IV) to SC switch achieving Priority Review designation, based on the pivotal Phase 3 PALOMA-3 and supportive Phase 2 PALOMA-2 studies. Efficacy results like these have not been seen before in a study assessing IV and SC comparability. Incredible progress from the team, and all our committed physicians and patients working with us on this. It is our joint mission to setting a new standard of care for patients with #NSCLC. Read more about the submission here: https://bit.ly/3yPDmVr   #JNJOncology #MyCompany

#InternationalChildhoodCancerDay2024 offically starts TOMORROW🌏🌟🎗️ Today, we raise awareness for one of the rarest diseases with less than 60 people diagnosed per year in the US, #ATRT 💛🤍 Atypical Teratoid Rhabdoid Tumor, ATRT, is ultra-rare, one of the most aggressive forms of brain tumors that is usually diagnosed in children under the age of 3. Despite the urgent need, there have been NO drugs developed and approved specifically to treat malignant pediatric brain tumors like #ATRT An urgent⚠️and unmet need for this community, and for other pediatric patients with malignant brain tumors, is for the development of safe and effective cancer treatment options. 💛🎗️ Lantern Pharma Inc. (Nasdaq: LTRN) and our subsidiary Starlight Therapeutics are committed to shifting the narrative for drug development for pediatric brain tumor patients, starting from our drug candidate, LP-184. One way we are doing this is by leveraging #AI to help develop novel and effective therapies to help create meaningful change for these patients fighting the awful disease🎗️ To learn more about Lantern and Starlight’s promising therapies for brain and CNS cancers visit our websites: Lantern Pharma: https://lnkd.in/ggDwK-gD Starlight Therapeutics: https://lnkd.in/gb-_5CTA #Childhoodcancerawareness #LP184 #LP284 #LanternXStarlight #GOGOLDFORCHILDHOODCANCER #Hope4ATRT

Oncology Care Partners follows a Value-Based Care model to treating Cancer patients. This approach puts aside competitive practices to enhance treatment quality and cost-effective management processes to address individual medical needs. Ultimately, optimal treatment outcomes are prioritized while aiming to improve overall patient well-being. Learn more at the link below: https://lnkd.in/gMgDTTay